Neuroimaging in Parkinson’s Disease and Related Disorders
- 1st Edition - November 6, 2022
- Imprint: Academic Press
- Editors: Marios Politis, Heather Wilson, Edoardo Rosario de Natale
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 6 5 1 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 6 5 2 - 1
Neuroimaging in Parkinson’s Disease and Related Disorders discusses the advances of molecular, structural and functional neuroimaging techniques associated with the etiology,… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNeuroimaging in Parkinson’s Disease and Related Disorders discusses the advances of molecular, structural and functional neuroimaging techniques associated with the etiology, pathophysiology, effects and complications of novel therapies in Parkinson’s and related disorders. With new neuroimaging methodologies emerging over the past five years, this book provides a comprehensive overview of new technologies and research. Sections discuss the biomarker value of neuroimaging of the brain to understand disease progression in vivo in actual patients with Parkinson’s disease and related disorders. Readers will be updated on in vivo pathology and pathophysiology in Parkinson’s disease and in a number of related disorders.
Also discussed is the association between clinical symptoms, clinical progression, and molecular, structural, and functional changes in the brain of patients with Parkinson’s disease and related disorders.
- Comprehensive overview of biomarker value of neuroimaging of the brain to understand disease progression in vivo in actual patients with Parkinson’s disease and related disorders
- Helps readers understand the in vivo pathology and pathophysiology in Parkinson’s disease and in a number of related disorders
- Discusses the association between clinical symptoms, clinical progression, and molecular, structural, and functional changes in the brain of patients with Parkinson’s and related disorders
Neurologists, neuroscientists, nuclear medicine professionals, Pharma researchers
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Section I. Introduction
- Chapter 1. Parkinson's disease and related disorders: the pursuit for reliable readouts and the role of neuroimaging
- Introduction
- Clinical aspects of movement disorders
- The future of neuroimaging and the application of robust measures in clinical trials
- Conclusion
- Chapter 2. Advances in magnetic resonance imaging
- Introduction
- Basic MRI physics
- T1, T2, and T2∗ relaxation
- Free induction decay
- MRI scanner hardware
- The magnet
- Radiofrequency coils
- Gradient coils
- Shim coils
- Image acquisition
- Spin echo and gradient echo
- Spatial localization gradients
- Inversion recovery
- Image reconstruction
- Echoplanar imaging and turbo spin echo
- Parallel imaging
- MRI modalities
- T1-weighted MR imaging
- T2-weighted MR imaging
- Diffusion-weighted imaging
- Functional MRI
- Arterial spin labeling
- Neuromelanin-sensitive MRI
- Susceptibility-weighted imaging
- Quantitative susceptibility mapping
- Magnetic resonance spectroscopy
- Conclusion
- Chapter 3. Advances in molecular neuroimaging methodology
- Introduction
- PET acquisition
- Quantitative PET analysis
- Advanced analysis methodology
- Conclusion
- Section II. Clinical applications in Parkinson's disease
- Chapter 4. Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease
- Introduction
- Molecular biology and imaging of the dopaminergic system
- Molecular imaging of the presynaptic dopaminergic terminals
- Molecular imaging of the postsynaptic dopaminergic terminals
- Conclusive remarks
- Chapter 5. Serotonergic molecular imaging in familial and idiopathic PD
- Introduction
- Serotonergic system changes in Parkinson's disease
- Molecular imaging of serotonergic system
- Serotonergic molecular imaging of motor symptoms
- Serotonergic molecular imaging of nonmotor symptoms
- Serotonergic molecular imaging of prodromal stages of Parkinson's disease
- Conclusions
- Chapter 6. Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson’s disease
- Introduction
- Glucose metabolism
- Synaptic pathology
- Neurotransmitter systems
- Phosphodiesterase
- Neuroinflammation
- Protein aggregation
- Energy dysregulation
- Conclusion
- Chapter 7. Structural MRI in familial and idiopathic PD
- Introduction
- Structural volumetric MRI
- Cortical thickness
- Structural MRI changes in familial Parkinson’s disease
- Diffusion MRI studies in idiopathic Parkinson’s disease
- Diffusion tensor imaging in familial Parkinson’s disease
- Neuromelanin-sensitive MRI in idiopathic Parkinson’s disease
- Neuromelanin-sensitive MRI in familial Parkinson’s disease
- Iron-sensitive MRI studies in idiopathic Parkinson’s disease
- Iron-sensitive MRI studies in familial Parkinson’s disease
- Arterial spin labeling in idiopathic Parkinson’s disease
- Summary
- Chapter 8. Functional MRI in familial and idiopathic PD
- Introduction
- rs-fMRI of motor symptoms in idiopathic Parkinson's disease
- As PD progresses, different FC changes in the brain can occur: multiple cross-sectional and longitudinal studies
- rs-fMRI of non-motor symptoms in idiopathic Parkinson's disease
- rs-fMRI studies in familial Parkinson's disease
- Task-based fMRI
- Motor tb-fMRI in idiopathic Parkinson's disease patients
- Cognitive tb-fMRI in idiopathic Parkinson's disease patients
- tb-fMRI studies in familial Parkinson's disease
- Conclusions
- Chapter 9. Molecular imaging in prodromal Parkinson’s disease
- Introduction
- Definition of prodromal Parkinson’s disease
- Dopaminergic imaging of prodromal Parkinsonism
- Molecular imaging of brain metabolism in prodromal Parkinson’s disease
- Serotonergic molecular imaging of prodromal Parkinson’s disease
- Molecular imaging of other neurotransmettitorial systems in prodromal Parkinson’s disease
- Conclusions
- Section III. Clinical applications in lewy body dementias
- Chapter 10. Molecular imaging evidence in favor or against PDD and DLB overlap
- Introduction
- PET markers of synaptic dysfunction
- PET markers of amyloidosis
- PET markers of tauopathy
- PET markers of dopaminergic dysfunction
- PET markers of cholinergic dysfunction
- PET markers of noradrenergic dysfunction
- Conclusions
- Chapter 11. Magnetic resonance imaging in Parkinson's disease with mild cognitive impairment, Parkinson's disease dementia, and dementia with Lewy bodies
- Introduction
- Structural MRI
- Diffusion tensor imaging
- Iron quantification MRI
- Functional MRI studies
- Conclusions
- Section IV. Clinical applications in atypical parkinsonian disorders
- Chapter 12. Neuroimaging in multiple system atrophy
- Introduction
- Magnetic resonance imaging
- Molecular imaging techniques
- Conclusions and future directions
- Chapter 13. Neuroimaging in progressive supranuclear palsy
- Introduction
- Structural magnetic resonance imaging
- Functional magnetic resonance imaging
- Magnetic resonance spectroscopy
- Molecular imaging studies in progressive supranuclear palsy
- Conclusion
- Chapter 14. Neuroimaging in corticobasal syndrome
- Introduction
- Structural magnetic resonance imaging
- Functional magnetic resonance imaging
- Single-photon emission computed tomography
- Positron emission tomography
- Conclusion and future directions
- Section V. Clinical applications in other movement disorders
- Chapter 15. Molecular imaging in Huntington's disease
- Introduction
- Brain metabolism
- Dopaminergic system
- Neuroinflammation
- Phosphodiesterases
- Opioidergic system
- GABAergic system
- Cannabinoid system
- Adenosinergic system
- Synaptic pathology
- Use of molecular imaging to track disease progression in Huntington's disease
- Use of molecular imaging as outcome measure in Huntington's disease trials
- Future perspectives of molecular imaging in Huntington's disease
- Chapter 16. Magnetic resonance imaging in Huntington's disease
- Introduction
- Structural MRI markers of disease pathology in Huntington's disease
- Magnetization transfer imaging
- Functional MRI markers of disease pathology in Huntington's disease
- Resting-state fMRI
- Task-based fMRI
- Arterial spin labeling
- Iron
- Magnetic resonance spectroscopy
- The use of MRI to track disease progression in Huntington's disease
- The use of MRI as outcome measures and for stratification in Huntington's disease trials
- Conclusion
- Chapter 17. Neuroimaging in essential tremor
- Introduction
- MRI markers of essential tremor
- Molecular imaging markers of essential tremor
- Conclusion
- Chapter 18. Neuroimaging of restless legs syndrome
- Introduction
- Molecular imaging in restless legs syndrome
- Magnetic resonance imaging in restless legs syndrome
- Conclusions
- Chapter 19. Neuroimaging in dystonia
- Introduction
- Magnetic resonance imaging markers of dystonia
- Volumetric MRI
- Cortical thickness
- Diffusion tensor imaging
- Iron-sensitive MRI
- Task-based fMRI
- Resting-state functional MRI
- Conclusion
- Chapter 20. Demyelinating syndromes and movement disorders
- Introduction
- Multiple sclerosis
- Movement disorders in other primary demyelinating diseases
- Diagnostic flowchart
- Management
- Summary
- Index
- Edition: 1
- Published: November 6, 2022
- No. of pages (Hardback): 610
- No. of pages (eBook): 610
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128216514
- eBook ISBN: 9780128216521
MP
Marios Politis
University of Exeter, United Kingdom
Marios Politis is a Professor of Neurology, Consultant Neurologist, the Director of Mireille Gillings Neuroimaging Center, and the Director of the Neurodegeneration Imaging Group at University of Exeter. His research involves clinical observation and the use of PET and MR imaging as a method of investigating etiology, pathophysiology, and effects and complications of novel therapies in neurodegenerative disorders such as Parkinson’s disease. He has served as a chief investigator in a number of observational and interventional trials. Professor Politis has received a high number of awards and distinctions such as from the Movement Disorder Society, Royal College of Physicians, Society of Nuclear Medicine and Molecular Imaging, and European Academy of Neurology. He is a recipient of the John Stolk Award in Movement Disorders from the American Academy of Neurology.
Affiliations and expertise
University of Exeter, United KingdomHW
Heather Wilson
Heather Wilson, MSc. PhD, is a Senior Research Fellow at the Neurodegeneration Imaging Group, and Imaging Methodology Lead at the Mireille Gillings Neuroimaging Centre, University of Exeter.
Affiliations and expertise
Neurodegeneration Imaging Group and Mireille Gillings Neuroimaging Centre, University of Exeter, London, United KingdomEd
Edoardo Rosario de Natale
Edoardo Rosario de Natale is a Senior Clinical Research Fellow at the Neurodegeneration Imaging Group at University of Exeter, lead of the clinical applications at the Mireille Gillings Neuroimaging Centre and honorary Consultant at the Royal Devon & Exeter NHS Foundation Trust.
Affiliations and expertise
Neurodegeneration Imaging Group and Mireille Gillings Neuroimaging Centre, University of Exeter, London, United KingdomRead Neuroimaging in Parkinson’s Disease and Related Disorders on ScienceDirect